The U.S.. Food and Drug Administration announced approval of bemotrizinol, a chemical sunscreen filter that blocks both UVA and UVB radiation. the ingredient is praised for its photostability and gentler profile on sensitive skin, but the agency granted exclusive rights to a single manufacturer for a year and a half, meaning shoppers may not see it in products right away.

Bemotrizinol receives FDA nod with 18‑month exclusivity

According to the FDA announcement, bemotrizinol is the first new sunscreen filter cleared in the United States in over a decade. the regulator granted the ingredient an 18‑month exclusivity period, allowing only one company to incorporate it into commercial sunscreens during that window.

Stability edge over existing chemical filters

The agency highlighted that bemotrizinol remains chemically stable under sunlight,a notable improvemeent over many current organic filters that degrade and lose efficacy after prolonged exposure.. This stability translates to more consistent protection and potentially fewer re‑applications for users.

Limited to one manufacturer may delay market rollout

As reported, the exclusivity clause means that existing sunscreen brands will need to reformulate or wait for American versions of their products to include the new filter. Consumers could therefore face a gap of several months before bemotrizinol appears on store shelves.

What does the exclusivity mean for US consumers?

Experts note that while the approval is a scientific win , the short‑term market impact is muted. "Brands we already use may reformulate or we may get American versions of these products," one industry observer said,underscoring the lag between regulatory clearance and retail availability.